Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Biocon, Bristol-Myers Squibb Sign Pact for Experimental Oral Insulin Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2012 | 05:26am CET
   By Rumman Ahmed 
 

BANGALORE, India--Biocon Ltd. (532523.BY) Friday said it has entered into an agreement with Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) on a licensing deal for its experimental biopharmaceutical drug IN-105, which is an orally administered insulin.

Under the terms of the agreement, the New York-headquartered company will have the right to exercise an option to obtain a global license for IN-105 on the successful completion of mid-stage trials for the experimental drug by Biocon, the Indian company said in a statement.

Biocon, which develops biological treatments that use proteins manufactured in living cells, is India's largest biotechnology company by revenue.

It has been seeking alliances with other drug makers for further development of the experimental drug under a licensing agreement.

If Bristol-Myers Squibb decides to obtain the license for IN-105, the U.S. company will assume full responsibility for the development program, including all development and commercialization activities outside India, the statement said.

In return, Biocon will receive a license fee, potential payments when IN-105 achieves certain regulatory and commercial milestones, as well as royalties on commercial sales of IN-105 outside India, the statement added.

Biocon will retain exclusive rights to IN-105 in India.

Indian drug makers often seek to develop drugs in partnership with foreign companies because they can help finance costly and lengthy research. At the same time, global companies are keen to cooperate with Indian companies because of lower costs, the availability of skilled scientists in the South Asian country, as well as the prospect of adding new products to their portfolios.

Write to Rumman Ahmed at rumman.ahmed@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bristol Myers Squibb Co.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB CO
03/23 BRISTOL-MYERS SQUIBB COMPANY (OTCMKT : BMYMP) Files An 8-K Departure of Director..
03/23 BRISTOL MYERS SQUIBB CO : Change in Directors or Principal Officers (form 8-K)
03/23 FINDINGS FROM BRISTOL-MYERS SQUIBB C : An HCV Protease Inhibitor With Preferenti..
03/23 BRISTOL MYERS SQUIBB : Patent Issued for Crystalline Forms of N,N-Dicyclopropyl-..
03/23 BRISTOL MYERS SQUIBB : Patent Issued for Crystalline Form of N,N-Dicyclopropyl-4..
03/23 BRISTOL MYERS SQUIBB : Patent Issued for Sensitive Method to Analyse Free PEG-Ma..
03/23 BRISTOL MYERS SQUIBB : to Announce Results for First Quarter 2017 on April 27
03/22 BRISTOL MYERS SQUIBB : CytomX pen expanded $3.6B biobucks research deal
03/20 BRISTOL MYERS SQUIBB : and CytomX Therapeutics Extend Worldwide Collaboration to..
03/17 BRISTOL MYERS SQUIBB : and Pfizer Present Large Real-World Observational Analysi..
More news
Sector news : Pharmaceuticals - NEC
03:14a YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
03/23 TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/23 Bristol Failure Makes Small Dent In CXCR4-Blocking Approach
03/23 Pharma Development Budgets Grow As Roche Remains A Believer
03/21 Biotechs under pressure after Trump (again) decries high drug prices
03/21 Selling Or Trimming Reasons Within My 86 Stock Portfolio
03/20 IMMUNE SYNAPSE : Beautiful Under The Microscope, Kiss Of Death For A Cancer Cell
Advertisement
Financials ($)
Sales 2017 19 706 M
EBIT 2017 5 203 M
Net income 2017 4 660 M
Finance 2017 232 M
Yield 2017 2,92%
P/E ratio 2017 20,15
P/E ratio 2018 18,47
EV / Sales 2017 4,72x
EV / Sales 2018 4,51x
Capitalization 93 287 M
More Financials
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 55,3 $
Spread / Average Target -0,91%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-4.57%93 287
JOHNSON & JOHNSON9.28%341 301
ROCHE HOLDING LTD.7.52%219 164
PFIZER INC.5.57%204 201
NOVARTIS AG-0.94%196 550
MERCK & CO., INC.7.49%173 740
More Results